Medpace Holdings, Inc.

NASDAQ•MEDP

CEO: Dr. August James Troendle M.D.

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Listing Date: 2016-08-11

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Contact Information

5375 Medpace Way, Cincinnati, OH, 45227, United States

513-579-9911

www.medpace.com

Market Cap

$12.11B

P/E (TTM)

26.2

32.5

Dividend Yield

52W High

$628.92

52W Low

$284.48

52W Range

41%

Rank20Top 6.4%

6.1

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Strong • 6.1 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$706.60M+0.00%

4-Quarter Trend

EPS

$4.35+0.00%

4-Quarter Trend

FCF

$144.97M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Jumps Twenty Percent Net revenue reached $2.53B USD, marking a 20.0% increase, driven by strong activity in key therapeutic areas.

Net Income Grows Substantially Net income totaled $451.1M USD, increasing by $46.7M USD compared to the prior year results.

Backlog Conversion Strong Backlog grew 4.3% to $3.03B USD; $1.89B USD expected to convert to revenue in 2026.

New Business Awards Increase Gross new business awards totaled $2,646.8M USD, up from $2,230.0M USD in the prior year period.

Risk Factors

Contract Loss Adverse Effect Potential loss, delay, or non-renewal of contracts could negatively affect operating results and revenue realization.

Margin Pressure From Inflation Operating margins face risk from increased competitive pricing pressure or continued rise of inflation impacting expenses.

Key Customer Revenue Concentration Top ten customers account for 35.1% of net revenue; loss of large customer materially affects prospects.

Cybersecurity System Failure Risk Failures in information systems like ClinTrak or security breaches could materially limit operations and harm reputation.

Outlook

Strategy Focus CRO Market Aim to expand market share in growing Phase I-IV CRO market, focusing on Oncology and CNS areas.

Talent Acquisition Critical Attracting, developing, and retaining qualified professional and scientific staff is key component for sustaining organic growth.

Funding Operations Growth Expect existing cash, operating cash flow, and potential borrowings to fund operational growth and acquisitions.

Capital Spending Moderates Capital spending as percentage of revenue decreased 49 basis points to 1.24% for the fiscal year 2025.

Peer Comparison

Revenue (TTM)

CNC

$198.10B

+17.0%

FMS

$22.44B

-0.7%

THC

$21.46B

+4.6%

Gross Margin (Latest Quarter)

NBIX

98.3%

-0.5pp

ILMN

68.2%

-1.4pp

COO

67.9%

-10.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CNC	$27.63B	-4.3	-28.7%	20.2%
WAT	$23.15B	64.9	8.0%	21.3%
WST	$23.03B	43.2	17.9%	7.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

5.4%

Steady Growth

4Q Net Income CAGR

11.1%

Profitability Improving

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:Jul 20, 2026

EPS:$3.98

Revenue:$690.68M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data